PBLS Analyst Ratings
Parabilis Medicines, Inc. (PBLS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $3.13B, listed on NASDAQ, employing roughly 145 people, carrying a beta of 5.03 to the broader market. Fog Pharmaceuticals, Inc. Led by Mathai Mammen, public since 2026-06-10.
Analyst Ratings
In the October 2026 monthly count, 5 analysts rated PBLS: 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $40.00
- Median Target
- $40.00
- High
- $40.00
- Low
- $40.00
- Targets Published, Last 12 Months
- 2
Recent Price Targets
The 2 most recent of at least 2 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Jul 6, 2026 | Leerink Partners | Not named | $40.00 | $29.58 |
| Jul 6, 2026 | Guggenheim | Not named | $40.00 | $29.58 |
Quantitative Rating
PBLS carries a model grade of C (overall score 2 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read PBLS Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked PBLS analyst ratings questions
- What is the PBLS consensus price target?
- As of the latest aggregator update, Parabilis Medicines, Inc. (PBLS) carries a consensus 12-month price target of $40.00. Target ranges run from a low of $40.00 to a high of $40.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on PBLS?
- In the October 2026 monthly count, 5 analysts rated PBLS, and the distribution tilts to the Buy side: 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has PBLS seen?
- Recent ratings actions for PBLS are not currently in the snapshot.
- How do analyst targets affect PBLS options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.